Cargando…
Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
Rare diseases are an important public health issue with high unmet need. The introduction of the EU Regulation on orphan medicinal products (OMP) has been successful in stimulating investment in the research and development of OMPs. Despite this advancement, patients do not have universal access to...
Autores principales: | Annemans, Lieven, Aymé, Ségolène, Le Cam, Yann, Facey, Karen, Gunther, Penilla, Nicod, Elena, Reni, Michele, Roux, Jean-Louis, Schlander, Michael, Taylor, David, Tomino, Carlo, Torrent-Farnell, Josep, Upadhyaya, Sheela, Hutchings, Adam, Le Dez, Lugdivine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345269/ https://www.ncbi.nlm.nih.gov/pubmed/28283046 http://dx.doi.org/10.1186/s13023-017-0601-9 |
Ejemplares similares
-
TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases
por: Annemans, Lieven, et al.
Publicado: (2020) -
Together4RD position statement on collaboration between European reference networks and industry
por: Hedley, Victoria, et al.
Publicado: (2023) -
The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks
por: Evangelista, Teresinha, et al.
Publicado: (2016) -
Principles for consistent value assessment and sustainable funding of orphan drugs in Europe
por: Gutierrez, Laura, et al.
Publicado: (2015) -
Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
por: Mulberg, Andrew E., et al.
Publicado: (2019)